

PA DEPARTMENT OF HUMAN SERVICES
MAAC BRIEFING DOCUMENT
LIPOTROPICS, STATINS

Proposed Effective Date: January 5, 2026

Revisions are noted with a ~~strike through~~ for deletions and **bold and underline** for additions.

I. Requirements for Prior Authorization of Lipotropics, Statins

A. Prescriptions That Require Prior Authorization

Prescriptions for Lipotropics, Statins that meet any of the following conditions must be prior authorized:

1. A non-preferred Lipotropics, Statin. See the Preferred Drug List (PDL) for the list of preferred Lipotropics, Statins at: <https://papdl.com/preferred-drug-list>.
2. A Lipotropics, Statin with a prescribed quantity that exceeds the quantity limit. The list of drugs that are subject to quantity limits, with accompanying quantity limits, is available at: <https://www.pa.gov/en/agencies/dhs/resources/pharmacy-services/quantity-limits-daily-dose-limits.html>.
3. A Lipotropics, Statin when there is a record of a recent paid claim for another Lipotropics, Statin in the point-of-sale on-line claims adjudication system (therapeutic duplication).

B. Revisions to Review of Documentation for Medical Necessity

In evaluating a request for prior authorization of a prescription for a Lipotropics, Statin the determination of whether the requested prescription is medically necessary will take into account whether the beneficiary:

1. For a non-preferred Lipotropics, Statin, **one of the following:**
 - a. **For a non-preferred Lipotropics, Statin that contains only one active ingredient,** has a history of therapeutic failure of or a contraindication or an intolerance to the preferred Lipotropics, Statins
 - b. **For a non-preferred Lipotropics, Statin combination product that contains more than one active ingredient (e.g., amlodipine-atorvastatin, ezetimibe-simvastatin), has a clinical reason as documented by the prescriber why the individual active ingredients cannot be used concurrently;**

AND

2. For therapeutic duplication, **one** of the following:
 - a. Is being transitioned to or from another Lipotropics, Statin with the intent of discontinuing one of the drugs
 - b. Has a medical reason for concomitant use of the requested drugs that is supported by peer-reviewed medical literature or national treatment guidelines;

PA DEPARTMENT OF HUMAN SERVICES
MAAC BRIEFING DOCUMENT
LIPOTROPICS, STATINS

AND

3. If a prescription for a Lipotropics, Statin is for a quantity that exceeds the quantity limit, the determination of whether the prescription is medically necessary will also take into account the guidelines set forth in the Quantity Limits Chapter.

NOTE: If the beneficiary does not meet the clinical review guidelines listed above but, in the professional judgment of the physician reviewer, the services are medically necessary to meet the medical needs of the beneficiary, the request for prior authorization will be approved.

C. Clinical Review Process

Prior authorization personnel will review the request for prior authorization and apply the clinical guidelines in Section B. above to assess the medical necessity of a prescription for a Lipotropics, Statin. If the guidelines in Section B. are met, the reviewer will prior authorize the prescription. If the guidelines are not met, the prior authorization request will be referred to a physician reviewer for a medical necessity determination. Such a request for prior authorization will be approved when, in the professional judgment of the physician reviewer, the services are medically necessary to meet the medical needs of the beneficiary.